Aprea Therapeutics (NASDAQ:APRE) versus Ocugen (NASDAQ:OCGN) Head-To-Head Comparison

Ocugen (NASDAQ:OCGN) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Ocugen and Aprea Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1	0	4	0	2.60
Aprea Therapeutics	1	1	2	0	2.25

Ocugen presently has a consensus price target of $9.75, suggesting a potential upside of 457.14%. Aprea Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 644.25%. Given Aprea Therapeutics’ higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Ocugen.

Risk and Volatility

Ocugen has a beta of 2.75, suggesting that its stock price is 175% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Institutional & Insider Ownership

10.3% of Ocugen shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 4.3% of Ocugen shares are held by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Ocugen and Aprea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-2,626.38%	-123.83%
Aprea Therapeutics	-4,405.59%	-96.33%	-74.35%

Earnings and Valuation

This table compares Ocugen and Aprea Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41 million	130.12	-$67.85 million	($0.23)	-7.61
Aprea Therapeutics	$290,000.00	29.18	-$12.60 million	($1.98)	-0.37

Aprea Therapeutics has lower revenue, but higher earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.